The next generation of Covid19 vaccines could come in pill form as Israeli company Oramed Pharmaceuticals is poised to begin clinical trials of an oral version in Tel Aviv, according to the Times of Israel, but there is also a link to India.
An Israeli pharmaceutical company has developed an oral version of the alleged single dose vaccine, which is being developed by the Indian company Premas Biotech. It was previously announced that the vaccine created antibodies in pigs during testing.
According to the Times of Israel, the oral vaccine will help countries with limited infrastructure speed up vaccinations.
If it turns out that the oral Covid vaccine produced in Israel is productive, it will simplify the vaccination process, and it will also not require cold storage and the labor required to administer the injections.
The Times of Israel quoted Oramed CEO Nadav Kidron as saying it could “be a game changer.”
Meanwhile, the government recently said that vaccines currently in use in the country need to be stored at temperatures between two and eight degrees Celsius.
In a written response, the Minister of State for Health also said that there are 296 cold rooms and 57,640 ice refrigerators in the country.
This is enough to meet the need for vaccines for both COVID-19 vaccination and routine immunization, Pavar said.
When asked if the government has made any assessment that the existing cold store is sufficient to store Covid vaccines, she said the National Cold Chain Management Information System is a digital database of cold chain equipment supplied to states and allied territories. …
“The cold chain space requirements are estimated using this database to increase the additional cold chain space required to store Covid vaccine beyond the cold chain space required for storing conventional immunization vaccines over a temperature range of two degrees Celsius to eight degrees Celsius and over a temperature range from -15 to -25 degrees Celsius, ”the minister said.